About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Delivery
- Sub-Industry: N/A
- Exchange: NYSE
- Symbol: VRX
- Previous Close: $16.18
- 50 Day Moving Average: $15.01
- 200 Day Moving Average: $20.14
- 52-Week Range: $347,669,000.00 - $13.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 3.36
- P/E Growth: 0.33
- Market Cap: $5.63B
- Outstanding Shares: 347,669,000
- Beta: -0.17
- Net Margins: -22.17%
- Return on Equity: 43.81%
- Return on Assets: 4.92%
Companies Related to Valeant Pharmaceuticals International:
- Debt-to-Equity Ratio: 7.11%
- Current Ratio: 1.46%
- Quick Ratio: 1.12%
What is Valeant Pharmaceuticals International's stock symbol?
Valeant Pharmaceuticals International trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."
Where is Valeant Pharmaceuticals International's stock going? Where will Valeant Pharmaceuticals International's stock price be in 2017?
23 equities research analysts have issued 12-month target prices for Valeant Pharmaceuticals International's shares. Their predictions range from $11.00 to $105.00. On average, they anticipate Valeant Pharmaceuticals International's stock price to reach $30.23 in the next year.
What are analysts saying about Valeant Pharmaceuticals International stock?
Here are some recent quotes from research analysts about Valeant Pharmaceuticals International stock:
- Wells Fargo & Co analysts commented, "On February 15, 2017, after the close, the FDA approved Valeant's Siliq (brodalumab). We believe that investors should sell Valeant shares on the news given 1) the stock is up 19% in the past five days (inclusive of afterhours) vs. +2.3% for the S&P500; 2) the approval is already assumed in consensus models; 3) the label is worse than expected; and 4) we believe the REMS program is an unexpected negative that will limit use. In addition, our new survey conducted this week of doctors who were not yet aware of a REMS was already showing a negative outlook for the drug. In this note we outline some of the findings from our survey this week. Respondents indicated that even if Siliq had been approved without a restrictive label, they would only prescribe it to approximately 7% of patients. We believe that with the label and REMS program, the actual use will be an even smaller fraction of patients." (2/16/2017)
- RBC Capital Markets analysts commented, "Valeant will report Q4/16 results before markets open on February 28. We anticipate $2.37B in revenues, $1.05B in Adj. EBITDA, and $1.23 in Adj. EPS. We believe that the focus of VRX's Q4/16 release and conference call will be on 2017 guidance and how much lower it will be relative to 2016 results' Lowering price target to $22 largely owing to reduced derm outlook. Following our forecast revisions, our price target declines to $22 from $29. This is largely due to our lower derm forecast and weaker overall outlook. We have also lowered our EBITDA multiple from 8.25x to 8.0x, as we believe Valeant has heightened risk due to ongoing government investigations." (2/14/2017)
According to Zacks Investment Research, "Valeant’s lower-than-expected earnings in the second-quarter of 2016 were disappointing. Quarterly revenues were impacted by lower product sales from existing businesses and negative foreign exchange fluctuations. Valeant also incurred high R&D expenses due to development programs related to its dermatology portfolio, spending related to brodalumab, and programs acquired through the Salix acquisition. Nevertheless, the company has been active on the acquisition front over the last few years, which has been driving growth. Valeant’s efforts in venturing into the gastrointestinal disease & Women's Health Markets are also encouraging. However, Valeant has been in the spotlight since Aug 2015 for all the wrong reasons like a price hike of specialty drugs, erroneous financial reporting, and termination of contracts with Philidor Rx Services." (8/16/2016)
Jefferies Group LLC analysts commented, "VRX missed cons revs & EPS ests by 2% & 5% as the US derm/GI businesses remained sluggish. That said, EPS grew 10% Q/Q to reach $2.66 (39% of FY16 guidance). And there were some encouraging signs – with mgt delivering cost efficiencies, paying down another $880M in debt, selling modest sized non- core assets, deploying new initiatives to improve its derm/GI businesses, and offering a realistic pathway towards reaching debt obligations through 2017. 2016 Guidance Unchanged and It Remains Back Loaded; Can Mgt Deliver Despite Some Clear Headwinds?: Despite the Q2 miss relative to consensus, mgt maintained its full year rev & EPS guidance of $9.9-10.1B and $6.60-$7.00. Mgt cited 2H tailwinds from seasonality (e.g., derm), expectations of improved performance in US dermatology and GI following recent initiatives, front loaded R&D spend, and improved cost efficiencies as key reasons. Moreover, they expect to reach these targets despite the ongoing genericization of Ziana and Zegerid and likely loss of exclusivity to Nitropress in 4Q16." (8/10/2016)
Morgan Stanley analysts commented, "We provide perspectives on ten known unknowns and thoughts on Philidor investigations (details in body of report). When will it be safe to go back into the water? Will the 10-K be filed by the end April as planned? What will (and will not) be in the 10-K? What really happened at Philidor, and will there be 10-K disclosures beyond financial restatements? Why did the Valeant Board do a seemingly abrupt about-face on former CFO Howard Schiller, and how will the dispute be resolved? How will Valeant’s $31B debt burden be significantly relieved, and will there be dis-synergies? How will Valeant perform vs. guidance issued on March 15? Who will be the new CEO, and will that individual maintain guidance? How will Walgreens manage the conflict of interest between its Valeant deal and its partnerships with PBMs (e.g., OptumRx)? How will the payment of greater rebates impact 2017 US growth prospects? Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research." (3/28/2016)
Who owns Valeant Pharmaceuticals International stock?
Valeant Pharmaceuticals International's stock is owned by a number of of retail and institutional investors. Top institutional investors include Paulson & CO. Inc. (5.58%), Davis Selected Advisers (2.01%), Renaissance Technologies LLC (0.84%), FMR LLC (0.62%), Alyeska Investment Group L.P. (0.43%) and Saba Capital Management L.P. (0.29%). Company insiders that own Valeant Pharmaceuticals International stock include Anne Clem Whitaker, Argeris N Karabelas, Joseph C Papa, Pavel Mirovsky, Pershing Square Capital Manage, Robert L Rosiello, Robert Roswell Chai-Onn, Ronald Harold Farmer and Thomas W Sr Ross.
Who sold Valeant Pharmaceuticals International stock? Who is selling Valeant Pharmaceuticals International stock?
Valeant Pharmaceuticals International's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Davis Selected Advisers, I.G. Investment Management LTD., Franklin Resources Inc., Scepter Holdings Inc., Fiera Capital Corp, Van ECK Associates Corp and AQR Capital Management LLC.
Who bought Valeant Pharmaceuticals International stock? Who is buying Valeant Pharmaceuticals International stock?
Valeant Pharmaceuticals International's stock was purchased by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Renaissance Technologies LLC, City Financial Investment Co Ltd, Stonehill Capital Management LLC, Manikay Partners LLC, Folger Hill Asset Management LP, Arrowstreet Capital Limited Partnership and Saba Capital Management L.P.. Company insiders that have bought Valeant Pharmaceuticals International stock in the last two years include Anne Clem Whitaker, Argeris N Karabelas, Joseph C Papa, Robert L Rosiello, Ronald Harold Farmer and Thomas W Sr Ross.
How do I buy Valeant Pharmaceuticals International stock?
Shares of Valeant Pharmaceuticals International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Valeant Pharmaceuticals International stock cost?
One share of Valeant Pharmaceuticals International stock can currently be purchased for approximately $16.18.